The Company

Prof. Theo Lasser

Co-founder and Chairman of the Board

Full Professor and Head of the Laboratory of Biomedical Optics at EPFL, Theo is at the cutting edge of optical functional imaging methods for applications in life science and medicine. Theo has also several years of industry experience, including research and consulting for Carl Zeiss SA.

Dr. Davide Mauri

Member of the Board

Davide joined the Eurofin Group in 2009 as Head of Intellectual Property Management. He was responsible within Eurofin Capital for projects dealing with technology and health. He is now in charge for investments in health and medical technologies for Eurofin Ventures.

Davide has over 10 years of experience in biotech company management and technology transfer. Prior to joining Eurofin Capital, he was the Director a.i. of PACTT, the technology transfer office of the Lausanne University (Unil) and University Hospital of Lausanne (CHUV).

Previously, he was Operations and Production Director at Med Discovery SA in Geneva (Switzerland) and Chief Scientific Officer at Apotech Corp. in Lausanne. Davide holds a PhD in Immunology and Allergology from the University of Bern (Switzerland) as well as an eMBA in Management of Technology and Entrepreneurship from the EPFL in Lausanne.

Tim Dyer

Member of the Board

Tim is co-founder and chief financial officer of Addex Pharmaceuticals where he played a significant role in raising more than CHF260 million in capital including Addex IPO, 3 venture capital rounds and a PIPE transaction. Since founding in 2002 until 2008 he was also responsible for human resources and business development and oversaw the growth of the organization to more than 140 staff and signing of drug development partnerships with Merck & Co., Inc. and Johnson & Johnson.

Prior to joining Addex he spent 10 years with PricewaterhouseCoopers in the UK, Ex-Soviet Union and Switzerland. Tim is a member of the Swiss government innovation promotion agency coaching team and has extensive experience in finance and the building of start-up companies. He is a UK Chartered Accountant and holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Southampton.